Shin Nippon Biomedical Laboratories, Ltd. to Expand Research and Development Facilities! Location Agreement Signed with Kagoshima City!

Location Agreement Ceremony with Shin Nippon Biomedical Laboratories, Ltd.

Date: March 30, Reiwa 8 (2026) (Monday) 11:00 AM - 11:20 AM

Location: Special Conference Room, 2nd Floor, Main Building, Kagoshima City Hall

Attendees: Company… Ryoichi Nagata, Chairman and President, Shin Nippon Biomedical Laboratories, Ltd.

Kagoshima City… Takaaki Shimotsuru, Mayor

Witness… Takashi Kitamura, Director, Commerce, Labor and Fisheries Department, Kagoshima Prefecture

(Photo) Scene from the Location Agreement Ceremony

Overview of Shin Nippon Biomedical Laboratories, Ltd.

Shin Nippon Biomedical Laboratories, Ltd. was founded in Kagoshima City in September 1957 as Japan's first contract research organization for pharmaceutical development. Since then, the company has been developing its core business as a CRO (Contract Research Organization) that supports pharmaceutical development, including non-clinical studies¹, clinical trials², and new drug application procedures, for pharmaceutical and biotechnology companies.

This expansion of research facilities is due to the high evaluation of its rapid and stable non-clinical study implementation system, which has led to the acquisition of Preferred Vendor agreements (priority contract agreements) with major European and American pharmaceutical companies. Further expansion of orders is anticipated, necessitating this facility expansion. It is expected that this will promote the development of new drugs from Kagoshima to the world, and significantly contribute to job creation and regional revitalization in the city.

¹ Non-clinical studies: Studies to confirm the efficacy and safety of drugs under development before clinical trials².

² Clinical trials: Studies to confirm the efficacy and safety of drugs in humans.

³ CRO (Contract Research Organization): An organization that undertakes the operation and management of non-clinical studies¹ and clinical trials² from pharmaceutical companies, etc., and supports (acts on behalf of) drug development.

Overview of the Expanded Research and Development Facility Plan

(1) Facility Name: NHP Experimental Facility EU Experimental Building

(2) Location: Part of 2642-1 Miyano-ura Town, Kagoshima City, etc.

(3) Land Area: 11,384.98 m² (3,443.95 tsubo)

(4) Building Area: 11,765.18 m² (3,558.96 tsubo)

(5) Scheduled Start of Operations: November, Reiwa 9 (2027)

(6) Planned Number of Employees: 1,175 employees at Kagoshima Headquarters (including 85 new hires) *As of the 5th year

(7) Business Content: Non-clinical CRO business

Related URL

https://snbl.com/

Kagoshima City fully supports companies expanding in the fields of research and development facilities, information and communications, business processing centers/call centers, design and content production, and manufacturing!

【Contact Information】

Kagoshima City Industrial Creation Division, Business Location Section

11-1 Yamashita-cho, Kagoshima City, Kagoshima Prefecture, 892-8677

TEL: 099-216-1314

FAX: 099-216-1303

E-mail: yuuchi@city.kagoshima.lg.jp

Homepage: https://www.city.kagoshima.lg.jp/rich/index.html